Skip to main content
. 2021 Jun 23;12:3862. doi: 10.1038/s41467-021-24132-6

Fig. 5. SPAS-1+ T cells are increased in the blood following combination therapy and predict tumor outcome.

Fig. 5

Mice bearing TRAMP-C2 tumors were treated as in Fig. 4. a Representative SPAS-1 tetramer staining of CD8+ T cells in peripheral blood at days 0 and 14 following the indicated treatment. b The absolute number of SPAS-1+ T cells per 100 µl of blood was calculated at days 7, 14, and 21 following treatment and normalized to the baseline in each mouse at day 0. c Ratio of the number of SPAS-1+ T cells per 100 µl of the blood of each mouse at day 14 over the endpoint tumor size at day 21. Data in (b) represent blood tested in n = 8 individual mice/group. c n = 6–13 individual mice/group, with exact n shown for each group. Data pooled from four independent experiments. Bars represent mean ± S.E.M. Unpaired two-tailed Mann–Whitney test was performed; *p < 0.05, **p < 0.01 Source data are provided as a Source Data File.